PriceTargets.com logo

Ascendis Pharma A/S - ASND Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $195.00
  • Forecasted Upside: 36.68%
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 13 Buy Ratings
  • 0 Strong Buy Ratings
$142.67 As of 10/4/2024 01:00 AM ET
▲ +1.72 (1.22%)

This chart shows the closing price for ASND by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Ascendis Pharma A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ASND and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ASND

Analyst Price Target is $195.00
▲ +36.68% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Ascendis Pharma A/S in the last 3 months. The average price target is $195.00, with a high forecast of $289.00 and a low forecast of $140.00. The average price target represents a 36.68% upside from the last price of $142.67.

This chart shows the closing price for ASND for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 14 polled investment analysts is to moderate buy stock in Ascendis Pharma A/S. This rating changed within the last month from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
4/14/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
7/13/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
10/11/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
1/9/2024
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/8/2024
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/7/2024
  • 1 strong buy ratings
  • 12 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2024
  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/5/2024

Latest Recommendations

  • 0 strong buy ratings
  • 13 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/23/2024Bank of AmericaBoost TargetBuy ➝ Buy$175.00 ➝ $191.00
9/17/2024CitigroupBoost TargetBuy ➝ Buy$178.00 ➝ $207.00
9/17/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$264.00 ➝ $289.00
9/17/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$180.00 ➝ $200.00
9/17/2024OppenheimerReiterated RatingOutperform ➝ Outperform$180.00 ➝ $190.00
9/17/2024Evercore ISIBoost TargetOutperform ➝ Outperform$191.00 ➝ $205.00
9/16/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$170.00 ➝ $170.00
9/5/2024OppenheimerUpgradeMarket Perform ➝ Outperform$180.00
9/4/2024CitigroupLower TargetBuy ➝ Buy$193.00 ➝ $178.00
9/4/2024JPMorgan Chase & Co.Lower TargetOverweight ➝ Overweight$174.00 ➝ $165.00
9/4/2024TD CowenLower TargetBuy ➝ Buy$175.00 ➝ $157.00
9/4/2024Bank of AmericaBoost TargetBuy ➝ Buy$165.00 ➝ $175.00
9/4/2024Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$277.00 ➝ $264.00
9/4/2024Cantor FitzgeraldLower TargetOverweight ➝ Overweight$173.00 ➝ $170.00
8/26/2024Evercore ISIUpgradeStrong-Buy
8/21/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$170.00 ➝ $174.00
8/13/2024Jefferies Financial GroupBoost TargetBuy ➝ Buy$174.00 ➝ $196.00
8/13/2024The Goldman Sachs GroupBoost TargetBuy ➝ Buy$170.00 ➝ $195.00
6/25/2024TD CowenUpgradeHold ➝ Buy$156.00 ➝ $175.00
5/31/2024Stifel NicolausInitiated CoverageBuy$200.00
5/16/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$116.00 ➝ $140.00
5/15/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$173.00
5/3/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$260.00 ➝ $262.00
5/3/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$173.00
5/3/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$167.00 ➝ $170.00
4/22/2024Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$116.00 ➝ $116.00
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$173.00
4/2/2024JPMorgan Chase & Co.Boost TargetOverweight ➝ Overweight$165.00 ➝ $167.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$173.00
3/15/2024Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$196.00 ➝ $260.00
2/8/2024CitigroupBoost TargetBuy ➝ Buy$146.00 ➝ $182.00
2/8/2024WedbushBoost TargetOutperform ➝ Outperform$207.00 ➝ $225.00
2/6/2024Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$152.00 ➝ $173.00
1/8/2024WedbushReiterated RatingOutperform$202.00 ➝ $207.00
12/20/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$152.00
12/20/2023WedbushBoost TargetOutperform ➝ Outperform$200.00 ➝ $202.00
12/20/2023Jefferies Financial GroupInitiated CoverageBuy$150.00
12/19/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$137.00 ➝ $149.00
11/9/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$113.00 ➝ $116.00
11/8/2023WedbushReiterated RatingOutperform ➝ Outperform$192.00
10/31/2023WedbushReiterated RatingOutperform$192.00
10/9/2023HC WainwrightReiterated RatingBuy ➝ Buy
9/15/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$152.00
9/14/2023WedbushReiterated RatingOutperform$192.00
9/7/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$152.00
9/7/2023Bank of AmericaBoost Target$107.00 ➝ $113.00
9/6/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$109.00 ➝ $113.00
9/6/2023WedbushBoost TargetOutperform ➝ Outperform$187.00 ➝ $192.00
9/6/2023Wells Fargo & CompanyLower TargetOverweight ➝ Overweight$139.00 ➝ $134.00
8/7/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$109.00
7/31/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$109.00
7/24/2023Morgan StanleyReiterated RatingEqual Weight ➝ Equal Weight$109.00
6/2/2023WedbushBoost Target$186.00 ➝ $187.00
4/28/20233MReiterated RatingMaintains
4/28/2023Cantor FitzgeraldBoost Target$142.00 ➝ $152.00
4/12/2023Morgan StanleyLower Target$108.00 ➝ $107.00
4/5/2023CitigroupLower TargetBuy$163.00 ➝ $146.00
4/5/2023OppenheimerDowngradeOutperform ➝ Market Perform
4/4/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$151.00 ➝ $108.00
4/3/2023Bank of AmericaLower TargetBuy$132.00 ➝ $92.00
4/3/2023Credit Suisse GroupDowngradeOutperform ➝ Neutral
2/17/2023Credit Suisse GroupReiterated RatingOutperform$130.00
2/17/2023Morgan StanleyBoost TargetOverweight$148.00 ➝ $151.00
1/3/2023Wells Fargo & CompanyBoost TargetOverweight$169.00 ➝ $177.00
11/15/2022Morgan StanleyBoost TargetOverweight$146.00 ➝ $148.00
11/14/2022Leerink PartnersLower TargetOutperform$168.00 ➝ $148.00
11/14/2022WedbushBoost TargetOutperform$151.00 ➝ $164.00
11/7/2022Wells Fargo & CompanyLower TargetOverweight$172.00 ➝ $169.00
11/3/2022Morgan StanleyLower TargetOverweight$148.00 ➝ $146.00
11/3/2022OppenheimerBoost Target$144.00 ➝ $150.00
11/3/2022WedbushBoost Target$144.00 ➝ $151.00
11/3/2022Credit Suisse GroupBoost TargetOutperform$123.00 ➝ $130.00
11/3/2022CitigroupBoost TargetBuy$157.00 ➝ $163.00
10/27/2022Cantor FitzgeraldLower Target$184.00 ➝ $182.00
10/20/2022The Goldman Sachs GroupInitiated CoverageBuy$174.00
9/22/2022Wells Fargo & CompanyBoost TargetOverweight$167.00 ➝ $172.00
9/21/2022Cantor FitzgeraldReiterated RatingOverweight
8/30/2022Berenberg BankReiterated RatingBuy$166.00
8/11/2022Morgan StanleyLower TargetOverweight$152.00 ➝ $148.00
8/11/2022OppenheimerLower TargetOutperform$154.00 ➝ $144.00
8/11/2022Leerink PartnersLower TargetOutperform$174.00 ➝ $168.00
5/12/2022Cantor FitzgeraldLower Target$230.00 ➝ $180.00
5/12/2022OppenheimerLower Target$166.00 ➝ $154.00
5/12/2022Wells Fargo & CompanyLower Target$190.00 ➝ $176.00
5/12/2022Credit Suisse GroupLower Target$194.00 ➝ $123.00
5/12/2022CitigroupLower Target$187.00 ➝ $158.00
4/1/2022Cantor FitzgeraldReiterated RatingOverweight
3/28/2022WedbushReiterated RatingOutperform
3/15/2022Morgan StanleyBoost TargetOverweight$180.00 ➝ $197.00
3/15/2022Leerink PartnersBoost TargetOutperform$190.00 ➝ $193.00
3/15/2022Bank of AmericaUpgradeNeutral ➝ Buy$148.00 ➝ $161.00
3/14/2022Wells Fargo & CompanyBoost Target$170.00 ➝ $190.00
3/14/2022Credit Suisse GroupBoost TargetOutperform$188.00 ➝ $194.00
3/7/2022Morgan StanleyLower TargetOverweight$197.00 ➝ $180.00
3/3/2022WedbushLower TargetOutperform$128.00 ➝ $117.00
3/3/2022Wells Fargo & CompanyLower TargetOverweight$176.00 ➝ $170.00
3/3/2022Credit Suisse GroupLower TargetOutperform$196.00 ➝ $188.00
2/28/2022CitigroupInitiated CoverageBuy$187.00
2/14/2022OppenheimerUpgradeMarket Perform ➝ Outperform$170.00
1/13/2022WedbushLower Target$191.00 ➝ $186.00
1/6/2022CowenInitiated CoverageMarket Perform
12/16/2021WedbushReiterated RatingOutperform$191.00
12/8/2021Wells Fargo & CompanyInitiated CoverageOverweight$176.00
11/18/2021Cantor FitzgeraldReiterated RatingOverweight
11/15/2021Leerink PartnersBoost TargetOutperform$182.00 ➝ $190.00
11/11/2021Credit Suisse GroupLower TargetOutperform$185.00 ➝ $179.00
10/20/2021Bank of AmericaDowngradeBuy ➝ Neutral$164.00 ➝ $169.00
8/26/2021WedbushReiterated RatingBuy$187.00
8/26/2021Morgan StanleyBoost TargetOverweight$197.00 ➝ $204.00
8/26/2021JPMorgan Chase & Co.Boost TargetOverweight$172.00 ➝ $175.00
8/26/2021Credit Suisse GroupBoost TargetOutperform$178.00 ➝ $185.00
8/26/2021Leerink PartnersBoost TargetOutperform$178.00 ➝ $182.00
7/21/2021Leerink PartnersLower TargetOutperform$181.00 ➝ $178.00
7/8/2021OppenheimerReiterated RatingHold
6/14/2021Leerink PartnersLower TargetPositive ➝ Outperform$191.00 ➝ $181.00
6/14/2021WedbushLower TargetOutperform$219.00 ➝ $189.00
6/14/2021Morgan StanleyLower TargetOverweight$201.00 ➝ $197.00
5/28/2021Credit Suisse GroupBoost TargetOutperform$176.00 ➝ $178.00
5/28/2021Morgan StanleyBoost TargetOverweight$199.00 ➝ $201.00
3/30/2021OppenheimerDowngradeOutperform ➝ Market Perform
3/11/2021Credit Suisse GroupLower TargetOutperform$178.00 ➝ $176.00
3/11/2021Stifel NicolausInitiated CoverageBuy
12/17/2020Berenberg BankInitiated CoverageBuy$216.00
11/13/2020Morgan StanleyBoost TargetOverweight$194.00 ➝ $199.00
11/12/2020Wells Fargo & CompanyBoost TargetOverweight$176.00 ➝ $190.00
11/12/2020Credit Suisse GroupBoost TargetOutperform$158.00 ➝ $178.00
11/12/2020Leerink PartnersBoost TargetOutperform$173.00 ➝ $191.00
10/13/2020Morgan StanleyBoost TargetOverweight$179.00 ➝ $194.00
9/30/2020WedbushBoost TargetOutperform$187.00 ➝ $206.00
9/14/2020JPMorgan Chase & Co.Initiated CoverageOverweight
8/31/2020Morgan StanleyBoost TargetOverweight$177.00 ➝ $179.00
8/28/2020Credit Suisse GroupBoost TargetOutperform$154.00 ➝ $158.00
7/15/2020Morgan StanleyLower TargetOverweight$181.00 ➝ $177.00
6/26/2020WedbushInitiated CoverageBuy$188.00
5/21/2020Morgan StanleyBoost TargetOverweight$180.00 ➝ $181.00
5/20/2020CSFBBoost TargetOutperform$149.00 ➝ $154.00
5/20/2020Leerink PartnersBoost TargetOutperform$170.00 ➝ $173.00
5/20/2020Credit Suisse GroupBoost TargetOutperform$149.00 ➝ $154.00
5/20/2020OppenheimerLower TargetOutperform$219.00 ➝ $208.00
4/20/2020Leerink PartnersBoost TargetPositive ➝ Outperform$152.00 ➝ $170.00
4/20/2020JPMorgan Chase & Co.Boost TargetOverweight$145.00 ➝ $150.00
4/20/2020OppenheimerBoost TargetOutperform$199.00 ➝ $219.00
4/20/2020Credit Suisse GroupBoost TargetIn-Line ➝ Outperform$139.00 ➝ $149.00
4/20/2020Cantor FitzgeraldBoost TargetOverweight$185.00 ➝ $201.00
4/20/2020Stifel NicolausBoost TargetBuy$146.00 ➝ $171.00
4/2/2020Morgan StanleyLower TargetOverweight$181.00 ➝ $180.00
3/27/2020Bank of AmericaReiterated RatingBuy$145.00
3/19/2020OppenheimerInitiated CoverageOutperform$199.00
2/26/2020Morgan StanleyBoost TargetOverweight$148.00 ➝ $181.00
1/17/2020Morgan StanleyBoost TargetOverweight$140.00 ➝ $148.00
12/17/2019Morgan StanleyBoost TargetOverweight$134.00 ➝ $140.00
12/3/2019Leerink PartnersReiterated RatingPositive ➝ Outperform$140.00 ➝ $152.00
11/19/2019WedbushReiterated RatingBuy$186.00
10/22/2019WedbushLower TargetPositive ➝ Outperform$191.00 ➝ $186.00
10/11/2019Morgan StanleyInitiated CoverageOverweight$128.00
(Data available from 10/6/2019 forward)

News Sentiment Rating

0.89 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 16 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
3/9/2024
  • 7 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/8/2024
  • 9 very positive mentions
  • 13 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2024
  • 12 very positive mentions
  • 14 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
6/7/2024
  • 9 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2024
  • 11 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2024
  • 13 very positive mentions
  • 20 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2024
  • 31 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2024

Current Sentiment

  • 31 very positive mentions
  • 27 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Ascendis Pharma A/S logo
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Read More

Today's Range

Now: $142.67
Low: $139.56
High: $142.80

50 Day Range

MA: $135.44
Low: $112.93
High: $153.43

52 Week Range

Now: $142.67
Low: $85.29
High: $161.00

Volume

340,459 shs

Average Volume

450,426 shs

Market Capitalization

$8.31 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Ascendis Pharma A/S?

The following Wall Street sell-side analysts have issued stock ratings on Ascendis Pharma A/S in the last year: Bank of America Co., Cantor Fitzgerald, Citigroup Inc., Evercore ISI, HC Wainwright, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Oppenheimer Holdings Inc., Stifel Nicolaus, StockNews.com, TD Cowen, The Goldman Sachs Group, Inc., Wedbush, and Wells Fargo & Company.
View the latest analyst ratings for ASND.

What is the current price target for Ascendis Pharma A/S?

13 Wall Street analysts have set twelve-month price targets for Ascendis Pharma A/S in the last year. Their average twelve-month price target is $195.00, suggesting a possible upside of 36.7%. Wells Fargo & Company has the highest price target set, predicting ASND will reach $289.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $140.00 for Ascendis Pharma A/S in the next year.
View the latest price targets for ASND.

What is the current consensus analyst rating for Ascendis Pharma A/S?

Ascendis Pharma A/S currently has 1 hold rating and 13 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ASND.

What other companies compete with Ascendis Pharma A/S?

Other companies that are similar to Ascendis Pharma A/S include BioNTech, Moderna, BeiGene, Teva Pharmaceutical Industries and Genmab A/S. Learn More about companies similar to Ascendis Pharma A/S.

How do I contact Ascendis Pharma A/S's investor relations team?

Ascendis Pharma A/S's physical mailing address is TUBORG BOULEVARD 12, HELLERUP G7, DK-2900. The biotechnology company's listed phone number is (457) 022-2244 and its investor relations email address is [email protected]. The official website for Ascendis Pharma A/S is www.ascendispharma.com. Learn More about contacing Ascendis Pharma A/S investor relations.